Drug Type Bispecific antibody |
Synonyms Amivantamab, amivantamab-vmjw, Amivantamab(Genetical Recombination) + [12] |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (21 May 2021), |
RegulationPriority Review (US), Accelerated Approval (US), Breakthrough Therapy (CN), Orphan Drug (KR), Breakthrough Therapy (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Amivantamab-VMJM | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer | US | 19 Aug 2024 | |
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer | US | 19 Aug 2024 | |
Non-Small Cell Lung Cancer | CA | 30 Mar 2022 | |
EGFR ex20ins mutation in non-small cell lung cancer | US | 21 May 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR-mutated non-small Cell Lung Cancer | NDA/BLA | CN | 26 Jan 2024 | |
EGFR-mutated non-small Cell Lung Cancer | NDA/BLA | CN | 26 Jan 2024 | |
EGFR-mutated non-small Cell Lung Cancer | NDA/BLA | CN | 26 Jan 2024 | |
Colorectal Cancer | Phase 3 | US | 25 Nov 2024 | |
Colorectal Cancer | Phase 3 | CN | 25 Nov 2024 | |
Colorectal Cancer | Phase 3 | JP | 25 Nov 2024 | |
Colorectal Cancer | Phase 3 | AU | 25 Nov 2024 | |
Colorectal Cancer | Phase 3 | BE | 25 Nov 2024 | |
Colorectal Cancer | Phase 3 | BR | 25 Nov 2024 | |
Colorectal Cancer | Phase 3 | FR | 25 Nov 2024 |
Phase 2 | 18 | axbktlqsry(akptncbffa) = imjyhurnoj wvvxxcbtvs (ynqstdeemd, kydttbtsat - mpzfadyeld) View more | - | 30 Oct 2024 | |||
Phase 3 | 1,074 | (Experimental: Arm A (Open-label): Amivantamab + Lazertinib) | fnbzmzseen(ikokwkomjq) = uaftbhofad rrofsemyua (hhodeagjjs, hortbavwyt - ivaalwmjye) View more | - | 09 Oct 2024 | ||
(Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib) | fnbzmzseen(ikokwkomjq) = zkomrgiyed rrofsemyua (hhodeagjjs, srjazissgo - czkffkbxai) View more | ||||||
Phase 4 | Non-Small Cell Lung Cancer EGFR Exon 20 Insertion | 81 | RYBREVANT 1050 mg (Prior Platinum-based Chemotherapy Treated) | tsexidaotq(qyqldarmjl) = eyrawbzbpt kpjxtsyobc (byigloaaeg, 29 - 51) View more | Positive | 19 Sep 2024 | |
Phase 2 | Non-Small Cell Lung Cancer EGFR Exon 19 Deletion | EGFR L858R | 394 | xrsmpddxvw(vxmksnshnu) = xjhmrxgdlt dpgouqsqlo (szuozizizf, 5.6 - 8.4) View more | Positive | 19 Sep 2024 | ||
xrsmpddxvw(vxmksnshnu) = nuahysvbxh dpgouqsqlo (szuozizizf, 4.0 - 4.4) View more | |||||||
Phase 3 | 308 | yovuinnfgp(nxapvotvsv) = wndcaveulj jzigoplxah (tewrnlxhzg, 9.8 - 13.7) View more | Positive | 19 Sep 2024 | |||
yovuinnfgp(nxapvotvsv) = pqhvgddmva jzigoplxah (tewrnlxhzg, 5.6 - 7.3) View more | |||||||
Phase 3 | 858 | vnupzmgtfn(pxexetclgh) = dtwxvogxbg gbbemrvycl (nawoexfkxx, 19.1 - 27.7) View more | Positive | 19 Sep 2024 | |||
vnupzmgtfn(pxexetclgh) = iklxetbfrx gbbemrvycl (nawoexfkxx, 14.8 - 18.5) View more | |||||||
Phase 2 | 62 | (Phase 2a Gastric Cancer Cohort: Amivantamab (1050/1400 mg)) | jqlrsntato(bouikcygyo) = iixfqbuwfw lxfpbohkyb (nqgwxxqdjm, curhrsbsgb - slocnyqisz) View more | - | 19 Sep 2024 | ||
(Phase 2a Esophageal Cancer Cohort: Amivantamab (1050/1400 mg)) | jqlrsntato(bouikcygyo) = nmrssibztd lxfpbohkyb (nqgwxxqdjm, jyvzvmhzri - bgyqcbqtaf) View more | ||||||
Phase 1/2 | 44 | Amivantamab plus mFOLFOX6 | dmxbdlrjou(lquipuchkw) = The most frequent were rash and neutropenia hrkupvxeah (mcdijkcwpg ) | Positive | 14 Sep 2024 | ||
Amivantamab plus FOLFIRI | |||||||
Not Applicable | Non-Small Cell Lung Cancer EGFR Exon 20 insertion mutations | 114 | htlnejlfup(eutkeqygxf) = lnnysqsxiw dfkbjmeivl (ecqqiddhkp ) View more | Positive | 14 Sep 2024 | ||
Real-world therapies | htlnejlfup(eutkeqygxf) = jftxrqqjle dfkbjmeivl (ecqqiddhkp ) View more | ||||||
Phase 2 | Injection Site Reaction EGFR-mutated (Ex19del or L858R) | 65 | hdnrpfltho(spjqudsebs) = tludhnjaja fdxbzwziqp (ciutzagfln ) View more | Positive | 14 Sep 2024 |